Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Melike Ceyhan Balci Sengul, Cem Sengul, Mehmet Emin Erdal, Ozlem Izci Ay, Muharrem Efe, Mustafa Ertan Ay & Hasan Herken. (2014) Association of the DRD2 TaqIA, 5-HT1B A-161T, and CNR1 1359 G/A Polymorphisms with Alcohol Dependence. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 24:2, pages 115-121.
Read now
Read now
Articles from other publishers (27)
Berhanu Geresu Kibret, Ana Canseco-Alba, Emmanuel S. Onaivi & Ephrem Engidawork. (2023) Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation. Frontiers in Behavioral Neuroscience 17.
Crossref
Crossref
Kayvan Ali Gharbi, Yvonne Ann Bonomo & Christine Mary Hallinan. (2023) Evidence from Human Studies for Utilising Cannabinoids for the Treatment of Substance-Use Disorders: A Scoping Review with a Systematic Approach. International Journal of Environmental Research and Public Health 20:5, pages 4087.
Crossref
Crossref
Jenny L. Wilkerson, Joshua A. Bilbrey, Jasmine S. Felix, Alexandros Makriyannis & Lance R. McMahon. (2021) Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?. Pharmacology Biochemistry and Behavior 206, pages 173192.
Crossref
Crossref
Javier Fernández-Ruiz, Ismael Galve-Roperh, Onintza Sagredo & Manuel Guzmán. (2020) Possible therapeutic applications of cannabis in the neuropsychopharmacology field. European Neuropsychopharmacology 36, pages 217-234.
Crossref
Crossref
Serge Weis, Michael Sonnberger, Andreas Dunzinger, Eva Voglmayr, Martin Aichholzer, Raimund Kleiser & Peter StrasserSerge Weis, Michael Sonnberger, Andreas Dunzinger, Eva Voglmayr, Martin Aichholzer, Raimund Kleiser & Peter Strasser. 2019. Imaging Brain Diseases. Imaging Brain Diseases
1243
1260
.
Pankaj Pandey, Kuldeep Roy, Haining Liu, Guoyi Ma, Sara Pettaway, Walid Alsharif, Rama Gadepalli, John Rimoldi, Christopher McCurdy, Stephen Cutler & Robert Doerksen. (2018) Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists. Molecules 23:10, pages 2630.
Crossref
Crossref
Alessandra Porcu, Miriam Melis, Rostislav Turecek, Celine Ullrich, Ignazia Mocci, Bernhard Bettler, Gian Luigi Gessa & M. Paola Castelli. (2018) Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gαi/o protein inhibitor. Neuropharmacology 133, pages 107-120.
Crossref
Crossref
Chrislean Jun Botanas, June Bryan de la Peña, Irene Joy dela Pena, Reinholdgher Tampus, Hee Jin Kim, Seong Shoon Yoon, Joung-Wook Seo, Eun Ju Jeong & Jae Hoon Cheong. (2015) Evaluation of the abuse potential of AM281, a new synthetic cannabinoid CB1 receptor antagonist. European Journal of Pharmacology 766, pages 135-141.
Crossref
Crossref
D. Matthew Walentiny, Robert E. Vann & Jenny L. Wiley. (2015) Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. Neuropharmacology 93, pages 237-242.
Crossref
Crossref
Rachel Allison Rabin & Tony Peter George. (2015) A review of co‐morbid tobacco and cannabis use disorders: Possible mechanisms to explain high rates of co‐use. The American Journal on Addictions 24:2, pages 105-116.
Crossref
Crossref
Brian S. Fulton. 2014. Drug Discovery for the Treatment of Addiction. Drug Discovery for the Treatment of Addiction
290
333
.
Javier Fernández‐Ruiz, Mariluz Hernández & Yolanda García‐Movellán. 2014. Cannabinoids. Cannabinoids
175
218
.
DM Walentiny, RE Vann, A Mahadevan, R Kottani, R Gujjar & JL Wiley. (2013)
Novel 3‐substituted rimonabant analogues lack Δ
9
‐tetrahydrocannabinol‐like abuse‐related behavioural effects in mice
. British Journal of Pharmacology 169:1, pages 10-20.
Crossref
Crossref
Rebecca M. Craft, Julie A. Marusich & Jenny L. Wiley. (2013) Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system?. Life Sciences 92:8-9, pages 476-481.
Crossref
Crossref
Kerri A. Schoedel, Carol Addy, Bijan Chakraborty, Kim Rosko, Stephanie Dunbar, Andrea Maes, Nancy Chen, Selwyn Aubrey Stoch, John Wagner, Jeff Chodakewitz & Edward M. Sellers. (2012) Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist. Journal of Clinical Psychopharmacology 32:4, pages 492-502.
Crossref
Crossref
Mónica Méndez‐Díaz, Pavel Ernesto Rueda‐Orozco, Alejandra Evelyn Ruiz‐Contreras & Oscar Prospéro‐García. (2010) The endocannabinoid system modulates the valence of the emotion associated to food ingestion. Addiction Biology 17:4, pages 725-735.
Crossref
Crossref
Peng Yang, Lirong Wang & Xiang-Qun Xie. (2012)
Latest advances in novel cannabinoid CB
2
ligands for drug abuse and their therapeutic potential
. Future Medicinal Chemistry 4:2, pages 187-204.
Crossref
Crossref
Erin B. Rasmussen, William Reilly, Jessica Buckley & & Steven R. Boomhower. (2012) Rimonabant reduces the essential value of food in the genetically obese Zucker rat: An exponential demand analysis. Physiology & Behavior 105:3, pages 734-741.
Crossref
Crossref
David A. Gorelick, Robert S. Goodwin, Eugene Schwilke, David M. Schwope, William D. Darwin, Deanna L. Kelly, Robert P. McMahon, Fang Liu, Catherine Ortemann-Renon, Denis Bonnet & Marilyn A. Huestis. (2011) Antagonist-Elicited Cannabis Withdrawal in Humans. Journal of Clinical Psychopharmacology 31:5, pages 603-612.
Crossref
Crossref
Torbjörn U. C. Järbe. 2011. Drug Discrimination. Drug Discrimination
241
285
.
Rebecca Stadel, Kwang H. Ahn & Debra A. Kendall. (2011) The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail. Journal of Neurochemistry 117:1, pages 1-18.
Crossref
Crossref
Jos H.M. Lange, Hans J. Sanders & Jeroen van Rheenen. (2011) An expedient atom-efficient synthesis of the cannabinoid CB1 receptor inverse agonist ibipinabant. Tetrahedron Letters 52:12, pages 1303-1305.
Crossref
Crossref
N.M.W.J. de Bruin, J.H.M. Lange, C.G. Kruse, A.H. Herremans, A.N.M. Schoffelmeer, M. van Drimmelen & T.J. De Vries. (2011) SLV330, a cannabinoid CB1 receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behavioural Brain Research 217:2, pages 408-415.
Crossref
Crossref
Carmen Manzanedo, Marta Rodríguez-Arias, Manuel Daza-Losada, Concepción Maldonado, María A Aguilar & José Miñarro. (2010) Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice. Behavioral and Brain Functions 6:1.
Crossref
Crossref
Javier Fernández‐Ruiz, Mariluz Hernández & José A. Ramos. (2010) Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders. CNS Neuroscience & Therapeutics 16:3.
Crossref
Crossref
Tricia H Smith, Laura J Sim‐Selley & Dana E Selley. (2010)
Cannabinoid CB
1
receptor‐interacting proteins: novel targets for central nervous system drug discovery?
. British Journal of Pharmacology 160:3, pages 454-466.
Crossref
Crossref
Charles W. Schindler, Leigh V. Panlilio, Joanne P. Gilman, Zuzana Justinova, V. Kiran Vemuri, Alex Makriyannis & Steven R. Goldberg. (2010) Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys. European Journal of Pharmacology 633:1-3, pages 44-49.
Crossref
Crossref